Addendum

Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11

Status
Status: Commission completed
Project no.
A26-73
Last updated

Report documents

  1. Addendum

    Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11

    published on
    Document type
    PDF document, 639 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-73_en

Dossier assessment

Indication:

Adult and paediatric patients 8 years of age and older with stage 2 type 1 diabetes mellitus, to delay the onset of stage 3

Result of dossier assessment:
  • Unchanged after addendum: For patients with a family history: added benefit not proven (based on the results of the relevant study)
  • Unchanged after addendum: For patients without a family history: added benefit not proven (no relevant study)

Additional information

Federal Joint Committee (G-BA)

06-08-2026 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A26-73
Commission
Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A26-73_en

Connected Projects

  1. Dossier assessment

    Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-11
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form